Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target

E-ISSN： 1873-4286|19|29|5314-5324

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.29, 2013-09, pp. : 5314-5324

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gut Microbiota as a Therapeutic Target for Metabolic Disorders

Current Medicinal Chemistry, Vol. 25, Iss. 9, 2018-03 ,pp. : 984-1001

Bentham Science Publishers

Access to resources Recommend Favorite

Modulation of the Maturing Gut Barrier and Microbiota: A Novel Target in Allergic Disease

Current Pharmaceutical Design, Vol. 14, Iss. 14, 2008-01 ,pp. : 1368-1375

Bentham Science Publishers

Access to resources Recommend Favorite

The CBS/CSE system: a potential therapeutic target in NAFLD?

Canadian Journal of Physiology and Pharmacology, Vol. 93, Iss. 1, 2015-01 ,pp. : 1-11

NRC Research Press

Access to resources Recommend Favorite

The Gut Microbiota as a Target for Improved Surgical Outcome and Improved Patient Care

Current Pharmaceutical Design, Vol. 15, Iss. 13, 2009-05 ,pp. : 1537-1545

Bentham Science Publishers

Access to resources Recommend Favorite

Commentary: Gut Microbiota and Brain Function: A New Target for Brain Diseases?

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 5, 2014-06 ,pp. : 733-735

Bentham Science Publishers

Access to resources Recommend Favorite